1. Merck's 15% decline in July presents an intermediate to long-term buying opportunity for investors. 2. Long-term trend lines and Bollinger Bands suggest strong support at $110, with an expected return to July's high of $133. 3. Sentiment indicators show a majority of investors expect lower prices, which is a positive sign for higher prices. 4. RSI levels indicate Merck is oversold for the intermediate term, suggesting a significant rally. 5. If the price target of $133 is reached, the article will reassess whether it's forming a double top or going higher.